Byrski et al. reported that pCR was observed in 65 out of 107 patients (61%), and that platinum-based chemotherapy is effective in a high proportion of patients with BRCA1-associated breast cancer [38], and potentially also for patients with TNBC tumors, including BRCA1/2 non-mutated tumors [39]. This evidence concerns the gene BRCA1 and breast carcinoma.